<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794443</url>
  </required_header>
  <id_info>
    <org_study_id>529-CL-028</org_study_id>
    <secondary_id>ONO-5920-05</secondary_id>
    <nct_id>NCT00794443</nct_id>
  </id_info>
  <brief_title>ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients</brief_title>
  <official_title>A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <brief_summary>
    <textblock>
      This is a multi-center double-blind parallel-group study in involutional osteoporosis
      patients to compare the efficacy and safety of monthly oral intermittent formulation
      ONO-5920/YM529 with its daily formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes in the lumbar vertebral bone mineral density (L2-4BMD) by the DXA method</measure>
    <time_frame>At the final evaluation point</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-course changes in the percent change of bone metabolism markers</measure>
    <time_frame>Through the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-course changes in the total femoral bone mineral density by the DXA method</measure>
    <time_frame>Through the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events, lab test values</measure>
    <time_frame>Through the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of fracture</measure>
    <time_frame>At the final evaluation point</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">692</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bone Loss, Age-Related</condition>
  <arm_group>
    <arm_group_label>1. Monthly - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly intermittent administration, dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Monthly - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly intermittent administration, dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM529 / ONO-5920</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. Monthly - Dose 1</arm_group_label>
    <arm_group_label>2. Monthly - Dose 2</arm_group_label>
    <arm_group_label>3. Daily</arm_group_label>
    <other_name>YM529</other_name>
    <other_name>ONO-5920</other_name>
    <other_name>Minodronic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose bone mineral density is &lt;70% of Young Adult Mean (YAM), or &lt;80% of YAM
             who have fragile fracture history

          -  Patients can walk on his/her own

          -  Written informed consent has been obtained from the patient.

        Exclusion Criteria:

          -  Sequential osteoporosis patients or patients with other disorders showing low bone
             mass

          -  Patients with the findings that influence measurement of lumbar vertebral bone mineral
             density by the DXA method

          -  Patients who are unable to keep raising or standing for â‰¥30 min

          -  Patients with peptic ulcer

          -  Patients who have experienced anamnesis or gastrectomy (total extraction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiomi Minamide</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Development Administration Dept., Astellas Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch.jsp</url>
    <description>Link to Results on JAPIC - enter 150712 in the JapicCTI-RNo. field (Japanese record)</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ONO-5920</keyword>
  <keyword>YM529</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Minodronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

